Daptomycin (lipopeptide): typically used for VRE and MRSA, but has had poor efficacy in clinical trials for CAP.
Proposed rationale: Daptomycin inserts into the membrane of gram-positive bacteria and artificial lipid vesicles. In the lungs, Daptomycin will insert into the lipid surfactant layer (which is abundant) due to lack of targeted specificity for the anti-microbial pathogens. Hence it will be effectively sequestrated and rendered inactive by pulmonary surfactant.
References
Mixed apneas are characterized by absent respiratory effort and airflow in the first section of…
Although rare, the differential diagnosis of hypoventilation and hypercapnia respiratory failure includes hypothyroidism. It is…
B-type natriuretic peptide (BNP) is a hormone created in response to cardiac wall stretch due…
A common finding described on computed tomography (CT) imaging. A disease with a peribronchovascular distribution…
Though often used synonymously; Trapped Lung and Lung Entrapment technically describe separate entities along the…
It is not clearly understood why patients with pulmonary hypertension (PH) develop pericardial effusions. However,…
This website uses cookies.